CAPABILITIES OF RADIATION METHODS IN NEUROFIBROMATOSIS DIAGNOSTICS
https://doi.org/10.35266/2949-3447-2025-4-2
Abstract
The paper analyzes the following modern approaches to neurofibromatosis visualization: magnetic resonance imaging, computed tomography, positron emission computed tomography, ultrasound scanning, and others. The article considers the role of radiological examination methods in medical screening, clinical course monitoring and therapy efficacy evaluation. Localized magnetic resonance imaging with contrast agents is the superior visualization technique for neurofibromatosis. Whole-body magnetic resonance imaging is effective for screening of asymptomatic tumors and total tumor mass calculation, while positron emission tomography is used to reliably diagnose malignant transformations of neurofibromas. Computed tomography is also beneficial in bone alternation detection and surgery planning where it is used as an addition to magnetic resonance imaging data. Ultrasound scanning is applicable for superficial tumor observation. Comparative analysis of scientific literature proves the key role of comprehensive use of diverse radiological examination methods in prompt neurofibromatosis diagnostics and screening, patients monitoring and therapy results evaluation.
About the Authors
A. A. Gaus
Surgut State University, Surgut
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor
S. P. Krushinin
Surgut City Clinical Hospital, Surgut
Russian Federation
Russian Federation
Radiologist
References
1. Wang M. X., Dillman J. R., Guccione J. et al. Neurofibromatosis from head to toe: What the radiologist needs to know // RadioGraphics. Radiological Society of North America. 2022. Vol. 42, no. 4. P. 1123–1144.
2. Макашова Е. С., Карандашева К. О., Золотова С. В. и др. Нейрофиброматоз: Анализ клинических случаев и новые диагностические критерии // Нервно-мышечные болезни. 2022. Т. 12, № 1. С. 39–48.
3. Ferner R. E., Huson S. M., Thomas N. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 // Journal of Medical Genetics. 2007. Vol. 44, no. 2. P. 81–88.
4. Campian J., Gutmann D. H. CNS Tumors in Neurofibromatosis // Journal of Clinical Oncology. 2017. Vol. 35, no. 21. P. 2378–2385. https://doi.org/10.1200/JCO.2016.71.7199.
5. Di Pietro S., Reali L., Tona E. et al. Magnetic resonance imaging of central nervous system manifestations of type 1 Neurofibromatosis: Pictorial review and retrospective study of their frequency in a cohort of patients // Journal of Clinical Medicine. 2024. Vol. 13, no. 11. P. 3311. https://doi.org/10.3390/jcm13113311.
6. Кутлянцева А. Ю., Кушнир Е. В. Нейрофиброматоз 1 типа. Отличия клинической картины нейрофиброматоза 1 типа у пациентов с различными вариантами наследования // Педиатрический вестник Южного Урала. 2021. № 1. С. 92–100.
7. Tamura R. Current Understanding of neurofibromatosis type 1, 2, and schwannomatosis // International Journal of Molecular Sciences. 2021. Vol. 22, no. 11. P. 5850. https://doi.org/10.3390/ijms22115850.
8. Рылов А. Редакционная статья. Нейрофиброматоз 1-го типа и его осложнение – плексиформные нейрофибромы // Русский журнал детской неврологии. 2023. Т. 18, № 1. С. 65–69.
9. Liao M., Lee H.-L., Liu Y.-L. et al. Neurofibromatosis type 1: A general review // Journal of Korean Neurosurgical Society. 2025. Vol. 68, no. 6. P. 644–651. https://doi.org/10.3340/jkns.2025.0073.
10. Webb M. J., Neth B. J., Webb L. M. et al. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related Schwannomatosis patients // Neuro-Oncology Advances. 2023. Vol. 5, no. 1. https://doi.org/10.1093/noajnl/vdad123.
11. Farschtschi S., Mautner V.-F., McLean A. C. L. et al. The neurofibromatoses // Deutsches Arzteblatt International. 2020. Vol. 117, no. 20. P. 354–360. https://doi.org/10.3238/arztebl.2020.0354.
12. Вашкевич А. А., Разнатовский К. И., Томашева А. О. и др. Случай нейрофиброматоза 1-го типа // Клиническая дерматология и венерология. 2022. Т. 21, № 6. С. 758–764.
13. Макашова Е. С., Золотова С. В., Карандашева К. О. и др. Проблемы Диагностики Нейрофиброматоза II Типа // Российский Нейрохирургический Журнал Имени Профессора А. Л. Поленова. 2022. Т. 14, № S1. С. 159.
14. Старосельцева О. А., Нуднов Н. В., Радутная М. Л. и др. Нейрофиброматоз II типа с вовлечением головного и спинного мозга // Вестник рентгенологии и радиологии. 2021. Т. 102, № 2. С. 98–108. https://doi.org/10.20862/0042-4676-2021-102-2-98-108.
15. Gallais S. I., Ferkal S., Lerman L. et al. [18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis //Orphanet Journal of Rare Diseases. 2021. Vol. 16, no. 1. 49 p. https://doi.org/10.1186/s13023-021-01680-0.
16. Usmani S., Riyami K. A., Numani S. P. et al. 18F-FDG PET/CT in Malignant peripheral nerve sheath tumours: Insights and clinical implications // JPMA. The Journal of the Pakistan Medical Association. 2025. Vol. 75, no. 5. P. 834–836. https://doi.org/10.47391/JPMA.25-39.
17. Geitenbeek R. T. J., Martin E., Graven L. H. et al. Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients // Journal of Neuro-Oncology. 2022. Vol. 156, no. 3. P. 559–567. https://doi.org/10.1007/s11060-021-03936-y.
18. Ahlawat S., Ly K. I., Fayad L. M. et al. Imaging evaluation of plexiform neurofibromas in neurofibromatosis type 1: A survey-based assessment // Neurology. 2021. Vol. 97, no. 7. P. 111–119. https://doi.org/10.1212/WNL.0000000000012437.
19. Baratto L., Hawk K. E., States L. et al. PET/MRI Improves management of children with cancer // Journal of Nuclear Medicine. 2021. Vol. 62, no. 10. P. 1334–1340. https://doi.org/10.2967/jnumed.120.259747.
20. Фёдорова А. А. Степанин М. А., Зубарев А. В. и др. Множественные нейрофибромы срединного и локтевого нервов (клинический случай) // Кремлевская Медицина. Клинический Вестник. 2021. № 2. С. 61–64.
21. Serafin Z., Machnikowska-Sokołowska M., Zawada E. et al. Recommendations of the Polish Medical Radiological Society regarding MRI in patients with plexiform neurofibromas in the course of neurofibromatosis type 1 // Polish Journal of Radiology. 2025. Vol. 90. P. 286–291. https://doi.org/10.5114/pjr/203005.
22. Miele G., Russo I., Filipponi L. et al. Clinical efficacy of selumetinib in alleviating neuropathic pain associated with plexiform neurofibroma: A case series // Genes. 2025. Vol. 16, № 6. P. 645.
23. Passos J., Soares M. P., Salgado D. et al. A single-center case study series assessing the effect of selumetinib use in patients with neurofibromatosis-related plexiform neurofibromas // Neuro-Oncology Advances. 2024. Vol. 6, no. 1. https://doi.org/10.1093/noajnl/vdae177.
24. Ahlawat S., Blakeley J. O., Langmead S. et al. Current status and ecommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis // Skeletal Radiology. 2020. Vol. 49, no. 2. P. 199–219. https://doi.org/10.1007/s00256-019-03290-1.
Review
For citations:
Gaus A.A., Krushinin S.P. CAPABILITIES OF RADIATION METHODS IN NEUROFIBROMATOSIS DIAGNOSTICS. Vestnik SurGU. Meditsina. 2025;18(4):13-21. (In Russ.) https://doi.org/10.35266/2949-3447-2025-4-2
Views:
26
Email this article 
